Beta-O2 is developing the ßAir Bio-artificial Pancreas, intended to cure Type 1 diabetes (TID).
Patients with TID are unable to produce insulin, a hormone needed to transport sugar into cells, providing the energy needed for daily life. ßAir provides a viable and safe environment for islets of Langerhans (insulin producing beta cells), to thrive and provide the body with insulin on demand. It is able to do so, as Beta-O2 has solved the major challenges of islet transplantation – creating a protective environment where the cells can thrive but where the patient doesn’t need to take life-long immunosuppression drugs with unpleasant side effects, and of crucial importance, keeping the cells alive and functioning inside the recipient’s body.
Company Details
- Employees
- 15
- Founded
- -
- Address
- 11 Amal St., P.o.b 11793,israel
- Phone
- 97239229917
- pr****@****-o2.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- beta-o2.com
- HQ
- Rosh Ha'ain, Other (Non US)
Beta-O2 Technologies Ltd. Questions
Beta-O2 Technologies Ltd.'s helpline number is 97239229917
Beta-O2 Technologies Ltd.'s website is beta-o2.com
Beta-O2 Technologies Ltd.'s LinkedIn profile is https://il.linkedin.com/company/beta-o2-technologies-ltd.
Beta-O2 Technologies Ltd. has
15 employees.
View email and phone details for 15
employees at Beta-O2 Technologies Ltd..
Beta-O2 Technologies Ltd.'s industry is
Biotechnology Research
Beta-O2 Technologies Ltd.'s top competitors are
Altucell,
Betalin Therapeutics Ltd.,
Seraxis,
Osiris Therapeutics,
Orgenesis Inc.,
Sernova,
Unicyte Ag,
Pharmacyte Biotech,
Nextcell Pharma Ab,
Viacyte.
Beta-O2 Technologies Ltd.'s support email address is press@beta-o2.com
Beta-O2 Technologies Ltd.'s categories are Biotechnology Research
Beta-O2 Technologies Ltd.'s founding year is 2004
